How does memantine work in the brain?
Memantine is an Alzheimer’s disease drug that works by blocking NMDA-type glutamate receptors, especially the receptor channels that open during pathological (excessive) glutamate signaling. By acting as an uncompetitive antagonist, it reduces calcium influx through NMDA receptors that can otherwise contribute to excitotoxic neuronal injury.[1][2]
Why does blocking NMDA receptors help?
Excess glutamate can overstimulate neurons and lead to damaging calcium entry. Memantine’s NMDA receptor blockade is designed to blunt this overactivation while limiting interference with normal synaptic signaling.[1][2]
What does “uncompetitive NMDA antagonism” mean?
Rather than simply preventing glutamate from binding, memantine preferentially blocks the NMDA receptor channel when it is activated. This allows it to target the high-activity state associated with excessive glutamate, which is thought to occur more during disease-related excitotoxicity than during typical neurotransmission.[1][2]
What other neurotransmitter systems does memantine affect?
Memantine’s primary, defining action is NMDA receptor antagonism. It is not used as a general “serotonin” or “dopamine” modulator; its clinical effect is tied mainly to its impact on glutamatergic signaling and excitotoxicity.[1][2]
How is this different from other Alzheimer’s drugs?
Cholinesterase inhibitors (like donepezil) increase acetylcholine signaling, while memantine targets glutamate/NMDA-mediated excitotoxicity. The different mechanisms are why they can be used together in some patients.[1]
Sources
- Memantine - StatPearls - NCBI Bookshelf
- Memantine - DrugBank